Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607)

Shanghai Pharmaceuticals Holding Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	271,272	259,152	231,240	215,824	191,423	185,963
Other Revenue	1,143	1,143	741.24	-	485.96	602.32
Revenue	272,416	260,295	231,981	215,824	191,909	186,566
Revenue Growth (YoY)	6.88%	12.21%	7.49%	12.46%	2.86%	17.27%
Cost of Revenue	242,271	229,366	201,604	187,416	165,671	160,102
Gross Profit	30,144	30,929	30,377	28,408	26,238	26,464
Selling, General & Admin	18,485	19,527	19,173	18,376	16,797	17,449
Research & Development	2,352	2,204	2,112	1,987	1,657	1,350
Other Operating Expenses	514.9	376.86	654.72	633.18	587.25	380.36
Operating Expenses	21,729	22,349	22,214	20,942	18,956	19,339
Operating Income	8,415	8,581	8,164	7,466	7,282	7,124
Interest Expense	-1,810	-1,885	-1,689	-1,518	-1,412	-1,405
Interest & Investment Income	811.88	461.83	971.41	2,150	1,265	887.8
Currency Exchange Gain (Loss)	11.41	11.41	21.51	10.1	-41.43	-16.14
Other Non Operating Income (Expenses)	-172.91	-109.59	-116.44	-128.71	-119.03	-119.11
EBT Excluding Unusual Items	7,255	7,059	7,351	7,979	6,974	6,471
Impairment of Goodwill	-	-	-	-19.21	-486.27	-704.76
Gain (Loss) on Sale of Investments	142.94	155.93	218.74	-206	116.8	122.16
Gain (Loss) on Sale of Assets	133.72	92.48	1,439	58.29	52.15	71.34
Asset Writedown	-169.32	-70.65	-322.79	-69.77	-15.77	-96.33
Legal Settlements	-12.69	-12.69	-37.38	-8.1	-34.82	-1.82
Other Unusual Items	-169.95	-169.95	160.13	409.61	569.14	400.4
Pretax Income	7,180	7,054	8,808	8,144	7,175	6,262
Income Tax Expense	1,944	1,888	1,816	1,869	1,570	1,432
Earnings From Continuing Operations	5,236	5,167	6,992	6,275	5,605	4,831
Minority Interest in Earnings	-1,211	-1,399	-1,375	-1,181	-1,109	-749.75
Net Income	4,025	3,768	5,617	5,093	4,496	4,081
Net Income to Common	4,025	3,768	5,617	5,093	4,496	4,081
Net Income Growth	-12.49%	-32.92%	10.28%	13.28%	10.17%	5.15%
Shares Outstanding (Basic)	3,726	3,701	3,483	2,842	2,842	2,842
Shares Outstanding (Diluted)	3,726	3,701	3,483	2,842	2,842	2,842
Shares Change (YoY)	-0.83%	6.28%	22.54%	-	-	0.45%
EPS (Basic)	1.08	1.02	1.61	1.79	1.58	1.44
EPS (Diluted)	1.08	1.02	1.61	1.79	1.58	1.44
EPS Growth	-11.57%	-36.77%	-10.06%	13.29%	10.03%	4.81%
Free Cash Flow	3,191	2,261	2,058	942.55	3,835	3,269
Free Cash Flow Per Share	0.86	0.61	0.59	0.33	1.35	1.15
Dividend Per Share	0.490	0.410	0.610	0.420	0.480	0.440
Dividend Growth	-19.67%	-32.79%	45.24%	-12.50%	9.09%	7.32%
Gross Margin	11.07%	11.88%	13.09%	13.16%	13.67%	14.18%
Operating Margin	3.09%	3.30%	3.52%	3.46%	3.79%	3.82%
Profit Margin	1.48%	1.45%	2.42%	2.36%	2.34%	2.19%
Free Cash Flow Margin	1.17%	0.87%	0.89%	0.44%	2.00%	1.75%
EBITDA	9,618	9,922	9,689	8,973	8,779	8,454
EBITDA Margin	3.53%	3.81%	4.18%	4.16%	4.57%	4.53%
D&A For EBITDA	1,203	1,341	1,526	1,507	1,496	1,330
EBIT	8,415	8,581	8,164	7,466	7,282	7,124
EBIT Margin	3.09%	3.30%	3.52%	3.46%	3.79%	3.82%
Effective Tax Rate	27.07%	26.76%	20.62%	22.95%	21.88%	22.86%

Source: S&P Capital IQ. Standard template. Financial Sources.